Forge Biologics, Inc
Clinical trials sponsored by Forge Biologics, Inc, explained in plain language.
Now part of
Ajinomoto Co., Inc.
2802
TOKYO
Gene therapy contract development and manufacturing organization.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy after stem cell transplant shows promise for rare brain disease Results expected Nov 2026 (estimated)
- Gene therapy boost for krabbe patients after transplant Results expected Nov 2026 (estimated)